Coronary Artery Dilatations and AneursymsASCADANCT07211854
Antithrombotic Strategies in Coronary Artery Dilatations and Aneurysms
An observational study of Coronary Artery Dilatations and Aneursyms, run by Franck Assayag at 1 site in France.
Trial summary
Objectives: The discovery of aneurysmal or ectatic lesions of the coronary arteries during coronary angiography or coronary CT angiography poses a triple challenge in terms of aetiology, treatment and prognosis. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Coronary Artery Dilatations and Aneursyms
- What is being tested?
- Anticoagulant Treatment
- How many people
- 51 participants
- Where
- 1 siteFrance
- Study dates
- 6 Sep 2024to 11 Sep 2024
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: A patient with aneurysmal or ectatic coronary disease with bi- or tri-truncular involvement on coronary angiography.
Who may be able to join
- Patient > 18 years old
- Patient living or deceased
- Patient with aneurysmal or ectatic coronary artery disease with bi- or tri-truncular involvement at coronary angiography.
Who cannot join
- Patient < 18 years old
- Monotruncal aneurysmal or ectatic disease
- Absence of coronary aneurysm / ectasia
- Patient's opposition to participation in research
Trial locations and contacts
1 site in 1 country.
About this study
Objectives: The discovery of aneurysmal or ectatic lesions of the coronary arteries during coronary angiography or coronary CT angiography poses a triple challenge in terms of aetiology, treatment and prognosis. The aim of this study, based on coronary angiograms performed over a 10-year period at the Centre Hospitalier de Versailles, was to determine which antithrombotic treatment was routinely prescribed to patients with ACC or AEC, the evolution of this long-term treatment, and to analyse the association between the presence/absence of anticoagulant treatment and the rates of ischaemic cardiovascular events and haemorrhagic complications.
Materials and methods: This is a non-interventional, observational, single-centre study conducted at the Versailles Hospital Centre from 2013 to 2023, based on the department's coronary angiography registry. The study included adult patients, living or deceased, hospitalised in the cardiology department who underwent coronary angiography between 1 January 2013 and 31 December 2023, which showed the presence of aneurysms or ectatic atheroma with bi- or tri-vessel coronary involvement.
- Being tested
- Anticoagulant Treatment
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Anticoagulant TreatmentOther
Also called Antiplatelet therapy
Follow-up of patients with coronary aneurysms and treatments introduced (anticoagulants and/or antiplatelet agents) to monitor the onset of ischaemic or haemorrhagic complications between 2013 and 2023.
| Study group | Role | What they receive |
|---|---|---|
| aneurysmal or ectatic lesions of the coronary arteries | This is a non-interventional, observational, single-centre study conducted at the Centre Hospitalier de Versailles from 2013 to 2023, based on the department's coronary angiography registry. The study included adult patients, both living and deceased, who were hospitalised in the cardiology department and underwent coronary angiography between 1 January 2013 and 31 December 2023, which showed the presence of aneurysms or ectatic atheroma with bi- or tri-vessel coronary involvement. Receives: Other: Anticoagulant Treatment |
What is being measured
The primary outcome is the main question the study is designed to answer.
The nature of the antithrombotic treatment prescribed between the initial hospital discharge and the follow-up date
The nature of the antithrombotic treatment prescribed between the initial hospital discharge and the follow-up date (anti-platelet agents alone, single or dual therapy, anticoagulant alone, anti-platelet agent-anticoagulant combinations).
Measured: Treatment on discharge from hospital and follow-up treatment beween 2013 and 2023
The nature of antithrombotic treatments
The nature of antithrombotic treatments
Measured: Discharge from hospital (day 1)
Secondary outcomes (2)
The occurrence of ischaemic cardiovascular events (cardiovascular death, myocardial infarction, unscheduled coronary revascularisation)
The occurrence of ischaemic cardiovascular events (cardiovascular death, myocardial infarction, unscheduled coronary revascularisation)
Measured: The follow-up period between 2013 and 2023
The occurrence of haemorrhagic events of any kind
The occurrence of haemorrhagic events of any kind
Measured: The follow-up period between 2013 and 2025
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted8 Oct 2025
- Study start6 Sep 2024
- Primary completion11 Sep 2024
- Study completion11 Sep 2024
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Coronary Artery Dilatations and AneursymsStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Retrospective
- Enrolment
- 51 participants (actual)
Sponsor and investigators
- Lead sponsor
- Franck Assayag
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor-investigator, Franck Assayag, Versailles Hospital
- Investigators
- Franck ASSAYAG, Principal investigator, Versailles Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07211854
- Sponsor's protocol ID
- P24/08_ASCADA
- Other IDs
- 2024-A01041-46
- Acronym
- ASCADA
- Status last verified
- Mar 2025
- First submitted
- 10 Aug 2025
- Last updated
- 8 Oct 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- Yes
Study at a glance
From the registry record, last updated by the sponsor on 8 Oct 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Antithrombotic Strategies in Coronary Artery Dilatations and Aneurysms
- ClinicalTrials.gov ID
- NCT07211854
- Acronym / sponsor ID
- ASCADA / P24/08_ASCADA
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 51 participants (actual)
- Lead sponsor
- Franck AssayagUniversity, hospital or other
- Study start
- 6 Sep 2024 (actual)
- Primary completion
- 11 Sep 2024 (actual)
- Study completion
- 11 Sep 2024 (actual)
- First posted
- 8 Oct 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Objectives: The discovery of aneurysmal or ectatic lesions of the coronary arteries during coronary angiography or coronary CT angiography poses a triple challenge in terms of aetiology, treatment and prognosis. The aim of this study, based on coronary angiograms performed over a 10-year period at the Centre Hospitalier de Versailles, was to determine which antithrombotic treatment was routinely prescribed to patients with ACC or AEC, the evolution of this long-term treatment, and to analyse the association between the presence/absence of anticoagulant treatment and the rates of ischaemic cardiovascular events and haemorrhagic complications.
Materials and methods: This is a non-interventional, observational, single-centre study conducted at the Versailles Hospital Centre from 2013 to 2023, based on the department's coronary angiography registry. The study included adult patients, living or deceased, hospitalised in the cardiology department who underwent coronary angiography between 1 January 2013 and 31 December 2023, which showed the presence of aneurysms or ectatic atheroma with bi- or tri-vessel coronary involvement.
Study design
- Observational model
- Cohort
- Time perspective
- Retrospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| aneurysmal or ectatic lesions of the coronary arteries | – | Other: Anticoagulant TreatmentThis is a non-interventional, observational, single-centre study conducted at the Centre Hospitalier de Versailles from 2013 to 2023, based on the department's coronary angiography registry. The study included adult patients, both living and deceased, who were hospitalised in the cardiology department and underwent coronary angiography between 1 January 2013 and 31 December 2023, which showed the presence of aneurysms or ectatic atheroma with bi- or tri-vessel coronary involvement. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- A patient with aneurysmal or ectatic coronary disease with bi- or tri-truncular involvement on coronary angiography.
Key inclusion criteria (3 listed)
- Patient > 18 years old
- Patient living or deceased
- Patient with aneurysmal or ectatic coronary artery disease with bi- or tri-truncular involvement at coronary angiography.
Key exclusion criteria (4 listed)
- Patient < 18 years old
- Monotruncal aneurysmal or ectatic disease
- Absence of coronary aneurysm / ectasia
- Patient's opposition to participation in research
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Anticoagulant TreatmentAlso: Antiplatelet therapyFollow-up of patients with coronary aneurysms and treatments introduced (anticoagulants and/or antiplatelet agents) to monitor the onset of ischaemic or haemorrhagic complications between 2013 and 2023. | Other | aneurysmal or ectatic lesions of the coronary arteries |
Primary outcome
The nature of the antithrombotic treatment prescribed between the initial hospital discharge and the follow-up date
Time frame: Treatment on discharge from hospital and follow-up treatment beween 2013 and 2023
The nature of the antithrombotic treatment prescribed between the initial hospital discharge and the follow-up date (anti-platelet agents alone, single or dual therapy, anticoagulant alone, anti-platelet agent-anticoagulant combinations).
The nature of antithrombotic treatments
Time frame: Discharge from hospital (day 1)
The nature of antithrombotic treatments
2 secondary outcomes
The occurrence of ischaemic cardiovascular events (cardiovascular death, myocardial infarction, unscheduled coronary revascularisation)
Time frame: The follow-up period between 2013 and 2023
The occurrence of haemorrhagic events of any kind
Time frame: The follow-up period between 2013 and 2025
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 8 Oct 2025.
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Franck ASSAYAG principal investigator
Versailles Hospital
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Coronary Artery Dilatations and Aneursyms, run by Franck Assayag at 1 site in France.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 8 Oct 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
The nature of the antithrombotic treatment prescribed between the initial hospital discharge and the follow-up date (time frame: Treatment on discharge from hospital and follow-up treatment beween 2013 and 2023). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 8 Oct 2025.